Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
| Autor: | McArthur, Grant A1 grant.mcarthur@petermac.org, Chapman, Paul B2, Robert, Caroline3, Larkin, James4, Haanen, John B5, Dummer, Reinhard6, Ribas, Antoni7, Hogg, David8, Hamid, Omid9, Ascierto, Paolo A10, Garbe, Claus11, Testori, Alessandro12, Maio, Michele13, Lorigan, Paul14, Lebbé, Celeste15, Jouary, Thomas16, Schadendorf, Dirk17, O'Day, Stephen J18, Kirkwood, John M.19, Eggermont, Alexander M20 |
|---|---|
| Zdroj: | Lancet Oncology. Mar2014, Vol. 15 Issue 3, p323-332. 10p. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|